Related Experiment Videos
[Extracorporeal shockwave lithotripsy (ESWL). Our experience]
A Frattini1, S Ferretti, F Arena
1Divisione di Urologia, Azienda Ospedaliera di Parma.
Acta Bio-Medica De L'Ateneo Parmense : Organo Della Societa Di Medicina E Scienze Naturali Di Parma
|January 1, 1995
Summary
This study shows that the Storz-Modulith SL 20 lithotripter achieved a 93% stone-free rate in 284 patients undergoing extracorporeal shock wave lithotripsy (ESWL) for kidney and ureteral stones.
Area of Science:
- Urology
- Medical Devices
- Nephrolithiasis Treatment
Context:
- Extracorporeal shock wave lithotripsy (ESWL) is a common treatment for kidney and ureteral stones.
- Evaluating the efficacy of third-generation lithotripters is crucial for optimizing patient outcomes.
- Technological advancements in stone localization (fluoroscopy and echography) can improve ESWL success rates.
Purpose:
- To report the clinical experience and outcomes of using the Storz-Modulith SL 20 lithotripter.
- To assess the effectiveness of this third-generation lithotripter in treating renal and ureteral stones.
- To evaluate the stone-free rates, treatment efficiency, and complication profile of the device.
Summary:
- A total of 284 patients with 149 renal and 135 ureteral stones were treated with the Storz-Modulith SL 20.
- 483 treatments were performed with a mean treatment rate of 1.7 sessions per patient.
- An overall stone-free rate of 93% was achieved, with a 2.5% complication rate and a 7% failure rate (20 patients).
Impact:
- The Storz-Modulith SL 20 demonstrates high efficacy in treating kidney and ureteral stones with a favorable stone-free rate.
- The study highlights the importance of advanced stone localization techniques in conjunction with lithotripsy.
- Low complication rates suggest a good safety profile for this lithotripter, contributing to minimally invasive urolithiasis management.